↓ Skip to main content

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Overview of attention for article published in Breast Cancer Research, July 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

news
1 news outlet
twitter
3 tweeters

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
116 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Published in
Breast Cancer Research, July 2019
DOI 10.1186/s13058-019-1154-8
Pubmed ID
Authors

Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 116 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 14%
Researcher 16 14%
Student > Bachelor 15 13%
Student > Master 13 11%
Other 7 6%
Other 12 10%
Unknown 37 32%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 25 22%
Medicine and Dentistry 17 15%
Pharmacology, Toxicology and Pharmaceutical Science 12 10%
Agricultural and Biological Sciences 6 5%
Chemistry 3 3%
Other 9 8%
Unknown 44 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2020.
All research outputs
#2,203,717
of 18,750,173 outputs
Outputs from Breast Cancer Research
#261
of 1,761 outputs
Outputs of similar age
#48,084
of 273,603 outputs
Outputs of similar age from Breast Cancer Research
#1
of 1 outputs
Altmetric has tracked 18,750,173 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,761 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,603 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them